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Sary We analysed antibodies specific for human p53 in sera from primary breast cancer patients using
three different immunoassays and we related these results to the p53 level in tumour tissue detected by
immunohistochemistry. Only 44% (11/25) of apparntly enzyme-linked immunosorbent assay (ELISA)-positive
sera were from patients with a high level of p53 protein in more than 50% of their tumour cells. Surprisingly,
36% (9/25) of the sera originated from patients with no detectable p53 protein at all. Immunoprecipitation
data suggested that the reason for this discrepancy is that at least some of the antibodies detected as positive
in the ELISA in these sera from patients with clinical stage I and stage II breast cancers may be induced by
immunogns other than p53 protein. Many of these reactions give apparently positive signals in a variety of
p53 assays, and very stringent analysis is required to avoid possible misinterpretation of these responses as a
p53-specific B-cell response in human cancer patients.
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Genetic analyses of human malignancies have revealed a
variety of significant changes, including the activation of
dominant oncogenes and alterations of tumour-suppressor
genes, as well as evidence of more general phenomena such
as DNA repair defects and genetic instability. The most
frequent specific moleular change is mutation and allele loss
occurring in the p53 tumour-suppressor gene. The clinical
significn ofp53 alterations has been extensively studied in
breast cancer because of the increasing incidence of breast
cancer, high mortality rate, long-lasting subclinical phase and
unsatisfactory treatment in the advanced stages. DNA-based
molcular analysis of p53 mutations and the detection of
abnormal levels of p53 protein in tumour tissue are useful
prognostic tests and could be meaningful therapeutic
indicators (Thor et al., 1992).
Interest in p53 as a prognostic markcer originated from the
work of Crawford et al. (1982), who reported that 9% of
sera from breast cancer patients contain detectable auto
antibodies to p53 protein. Subsequently there have been
reports of B-cell responses to p53 protein in patients with
diverse types of tumours (Caron de Fromentel et al., 1987;
Angelopoulou and Diamandis, 1992; Davidoff et al., 1992;
Hassapoglidou and Diamandi, 1992; Winter et al., 1992;
Lubin et al., 1993; Schlichtholz et al., 1994). In all these
studies the percentage of serologically positive cases ranged
from 2% to 25%. A major clinical question that emerges
from these observations is whether or not this group of
anti-p53 antibody-producing patients falls into any clnically
definable group as regards tumour behaviour and response to
treatmenL In order to assess this, it is very important to
carry out stringent serological analysis to detmine the
nature, specificity and quantity of antibodies being produced
by the tumour-bearing population.
Our aim was to analyse breast cancer sera from patients
with clinical stage I and II disease for the presence of p53
antibodies using three different immunoassays in order to
optmnise detection systems and establish whether there is any
link between the p53 level in tumour tissue and the p53
humoral response.
Materals as mtho
Sera and tumour tissue from 100 patients with histologically
determined breast carcinomas (clinical stage I and II) were
used. Eighty sera were collected from our Institute and the
remaining 20 sera were obtained from the Ludwig Institute
for Cancer Research in Sao Paulo. All samples were kept
deep frozen until further processing. Tumour samples were
fixed in methacarn and embedded in paraffin. Indirect
immunoperoxidase staining was performed on tumour tissue
using the monoclonal antibody (MAb) DO-1 (Vojtesek et al.,
1992).
Osteosarcoma cell lines HOS (expressing a high level of
mutant p53) and SAOS2 (no expression ofp53), the fibrosar-
coma cel line HS913T (no expression of p53), the vulval
carcinoma cell line A431 (expressing a high level of mutant
p53) and a SV40-transformed SVK14 cell line (expressng a
high level of wild-type p53) were cultured in Dulbecco's
modified Eagle medium (DMEM) supplemented with 10%
fetal calf serum (FCS). For metabolic labelling 80%
confluent cells were first grown for 30 min in DMEM with
10% FCS without L-cysteine and L-methionine and then
suplemented for 2 h with 20 #sCi ml-' [3SJmethionine (Gan-
non et al., 1990).
Human p53 protein was expressed either in Escherichia coli
under the control of the bacteriophage T7 RNA polymerase
promoter (Midgley et al., 1992) or in insect cells infected with
a recombinant baculovirus. These p53 proteins were purified
as described elswhere (Midgley et al., 1992; Hupp et al.,
1992).
Immunoprecipitation of the p53 protein from labelled cells
(lysis buffer: 150mM sodium chlonde 50 mM Tris pH 8.0,
5 mM EDTA, 1% NP40, 1 mM PMSF) with 2 and 4 uld of
the patients' sera and control MAbs was performed essen-
tially as described previously (Gannon et al., 1990). After
SDS-polyacrylamide gel electrophoresis the gels were stained
with Coomassie blue R250, destained, dried and autoradiog-
raphed on Kodak X-OMAT film.
For immunoblots either the total cellular protein lysates of
previously mentioned cell lines or purified p53 protein were
prepared in laemmli electrophoresis sample buffer then
separated by SDS-polyacrylamide gel eletrophoresis and
transferred onto nitrocellulose membranes. Human sera for
Western blotting were diluted 1:50 and 1:100 in DMEM with
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10% FCS. The blots were stained as described by Vojtesek et
al. (1992).
Antibody-captured immunoassay was used to detect the
anti-p53 antibody in the sera of the patients. In this ELISA
(Harlow and Lane, 1988) we used pure p53 protein (coating
solution concentration 4gg ml-') as the solid phase reagent
to detect p53 antibodies in the sera tested. Bovine serum
albumin as the irrelevant antigen was included in each
ELISA procedure to obtain a clear distinction between
specific binding and possible background binding of tested
sera.
Results
In this study we screened 100 sera from breast cancer
patients and normal sera for the presence of circulating p53
antibodies using Western blotting, ELISA and
immunoprecipitation. The results obtained with the three
techniques were compared and were related to the p53 level
in matched tumour tissue detected by immunohistochemistry.
The results are presented in Table I.
In the ELISA using recombinant wild-type p53 protein
purified from a baculovirus expression system as a solid
phase, 25 out of 100 sera (25%) were found to be p53
reactive in that they showed selective binding to the p53-
coated plates as opposed to the BSA-coated plates. The titre
of these sera in this assay was always very low (maximum
1:500 compared with a maximum of 1:10000 for specific
polyclonal antibodies raised against p53). Moreover there
was no clear relationship with the level of p53 in tumour
tissue. Nine of the apparently positive sera (36%) originated
from patients whose tumours contained no detectable p53
protein, and five other positive samples (20%) were from
patients whose tumours contained a very low level of p53
(weak staining in less than 25% of tumour cells). Thus only
44% of ELISA-positive sera (11/25) were from patients exp-
ressing a high level of p53 protein in more than 50% of the
tumour cells. Thus, there seems to be no causal relationship
between the presence of high levels of p53 in tumours and
the production of anti-p53 antibodies by patients as
measured by this assay.
On immunoblot analysis using pure p53 protein as well as
unlabelled protein extracts from cell lines HOS, A431,
SVK14 and HS913T, none of the sera tested detected p53.
However, since MAb DO-I and one of the five human
positive control sera (a gift from Dr H Kalthoff and Dr T
Soussi, data not shown) did detect p53, we can conclude that
our immunoblotting approach is both reliable and sensitive.
In order to obtain further insight into these unexpected
results, we performed immunoprecipitations on metabolically
labelled protein lysates from human cancer cell lines A431
and HOS expressing a high level of the mutant form of p53
and HS913T with no expression of p53. Only 13 out of 100
sera (13%) immunoprecipitated a 53 kDa protein from HOS
and A431 cell lysates, which co-migrated with p53 protein
immunoprecipitated by MAb DO-1. Of these, seven samples
were also positive in the ELISA. However, there was no
correlation between immunoprecipitation-positive sera and
p53 expression. since among immunoprecipitation-positive
samples there were both immunohistochemistry-positive mat-
ched tumours (8/13) as well as imnlunohistochemistry-
negative ones (5 13). Surprisingly. 12 out of 13
immunoprecipitation-positive sera revealed a clear reaction
corresponding to the 53 kDA protein band on the HS913T
cell lysate, in which there is no detectable p53 (Figure la and
b). This critical observation means that many human tumour
sera contain antibodies to a 53 000 molecular weight protein
that is not p53. If this control cell line had not been included
these sera would certainly have been considered positive.
That the protein present in the p53-negative cell line HS913T
is not p53 or antigenically closely related to it has been
confirmed by our failure to immunoprecipitate it with a
whole panel of other anti-p53 antibodies, both monoclonal
and polyclonal. recognising discrete epitopes on p53. This
non-p53 53 000 molecular weight protein recognised by the
tumour-bearing sera is also present in the p53-negative cell
line SOAS 2, which intense genetic analysis has confirmed









Fgwe 1 Immunoprecipitation from [35Sjmethionine-labelled
HOS cell extract (a) and HS913T cell extract (b).
Immunoprecipitation with control monoclonal antibody DO-I
(lane I in a and b). with patient sera no. 3 (lane 2 in a and b) and
with patient sera no. 12 (lane 3 in a and b).
p53-
Table I Detection of anti-p53 antibodies in sera from breast cancer patients
Human tumour cell lines
HS913T HOS A431
(no p53 (high level ofmutant (high level ofmutant
Methods used expression) P53) P53) Pure p53'
Immunoprecipitation
on labelled protein 12% 13% 13 ND
Western blotting 0'. 0% 0 0%
ELISA ND ND ND 25%
ND. not done. ap53 purified from insect cells as described in Materials and methods.AnibodI l p53 in bon! canwr paeub
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our sera from breast cancer patients we could with certainty
identify genuine p53-specific circulating antibodies in only
one patient (1%). This serum was positive in the ELISA and
immunoprecipitation assay but not in the immunoblotting
assays. If, however, we had only considered our ELISA
results with pure p53 protein or our immunoprecipitation
data without the p53 null cell line controls then we would
have detected 25% and 13% 'positive cases'.
The p53 status of breast cancer patients has been assessed by
various studies at the DNA and protein levels, and the data
so far suggest that there is a correlation between high p53
levels and unfavourable disease prognosis (Thor et al., 1992;
Alred et al., 1993; Vojtesek et al., 1993). The possible
immune self recognition of the aberrant p53 protein and
formation of specific antibodies in patient sera could poten-
tially provide a new approach in detecting p53 tumour-
related changes by means of a relatively simple serological
assay. However, while the immunogenicity of p53 protein in
xenogenic systems has been well established and can be
documented by a number of monoclonal antibodies
developed in various animal species immunised with p53
protein, the frequency of the production of autoantibodies to
p53 in humans is still unclear.
We report on the failure to detect circulating p53 autoan-
tibodies in a clinically meaningful number of mammary
cancer patients using three different immunoassays. Out of
100 breast cancer patient sera collected from two areas with
substantially different demographic characteristics (i.e. 80
sera from Europe and 20 sera from South America), cir-
culating p53 autoantibodies were clearly noted in only one
patient of European origin. This result is in apparent
disagreement with the findings of other authors (Crawford et
al., 1982; Caron de Fromentel et al., 1987; Angelopoulou and
Diamandis, 1992; Davidoff et al., 1992; Winter et al., 1992;
Lubin et al., 1993; Schlichtholz et al., 1994), who found p53
serum antibodies in a much higher, though variable, propor-
tion of breast cancer patients, ranging from 5% to 25% of
positive cases. Undoubtedly, differences in the assay systems,
the number ofpatients examined and genetic heterogeneity of
the patients studied might account for these variations in
results. Because of the limitations of individual assays and
possible misinterpretation of results, we included additional
negative controls, for example the use of lysates from cells
not expressing p53 enabled us to exclude several false-
positive findings. Our ELISA showed that 25% of the sera,
regardless of whether they originated from patients with
'p53-positive' or 'p53-negative' tumours, have antibodies
which apparently recognise human p53 protein. As this was
unexpected, we decided to confirm these 'positives' using
immunoprecipitation of labelled protein as this technique
could determine whether the antibodies recognise specific
conformational forms of the p53 protein. Using
imunoprecipitation we could conclude that at least some of
the antibodies detected in the sera of the patients are prob-
ably induced primarily against other immunogens and could
cross-react or not react at all with p53 protein. In particular,
we note the high frequency of sera that contain antibodies to
protein of 53000 molecular weight that is not p53.
The lack of correlation between ELISA p53 antibody-
positive sera and p53 expression in the matched tumour
tissue might support our speculation that either a certain
proportion of antibodies detected by ELISA reflect the B-cell
response to an as yet unknown antigen of approximately 53
kDa molecular weight or the specific p53 antibody formation
could in some individuals represent an autoimmune
phenomenon not related to the tumorigenic process. The
latter assumption is supported by a study by C Vennegoor et
al. (personal communication), who showed that sera from 4
out of 25 healthy persons (16%) contain autoantibodies to
linear epitopes of wild-type p53 protein. Further studies of
the presence of p53 antibodies in human sera will require
analyses ofhealthy control sera and very stringent serological
controls in order to be certain that a completely accurate
distinction between positive and negative samples is made.
Only then can the potential clinical significance of the finding
be judged. While it is clear that some patients do produce
antibodies that bind p53, our own results and those of
Hassapoglidou and Diamandis (1992), in contrast to those of
Crawford et al. (1982), Caron de Fromentel et al. (1987),
Angelopoulou and Diamandis (1992), Davidoff et al. (1992),
Winter et al. (1992), Lubin et al. (1993) and Schlichtholz et
al. (1994), seem to argue that the fraction of true positives in
these breast cancers is so low that the determination of p53
antibody status is unlikely to be ofmajor use in the detection
of occult disease. An important factor that could control the
level of genuine anti-p53 antibodies present in sera may be
the stage of the disease, since our study has specifically
focused on the arguably clinically more relevant stages. To
confirm this hypothesis we plan to carry out further studies
of late-stage patient sera.
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